A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Recruiting
AstraZeneca
Phase 1
This study will test an investigational drug called AZD1390 in combination with radiation
therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to
patients. This study will test safety, tolerability and PK (how the drug is absorbed,
distributed and eliminated) of ascending doses of AZD1390 in combination with distinct
regimens of radiation therapy
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Recruiting
Beatson West of Scotland Cancer Centre
Phase 1
CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the
recommended phase II dose (RP2D) and safety profiles of different DNA damage repair
inhibitors (DDRis) when given in an open label fashion in combination with fixed dose
curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC. The RP2D will
be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a
time to event continuous reassessment method (TiTE- CRM) model within each of the
experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to
13.5 months post start of radiotherapy and use these to inform dose escalation decision
making.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.